TY - JOUR
T1 - A Digital Intervention to Address Sexual Health in Hematopoietic Stem Cell Transplant Survivors
AU - El-Jawahri, Areej
AU - Reese, Jennifer B.
AU - Traeger, Lara
AU - Dizon, Don
AU - Cutler, Corey
AU - Bober, Sharon
AU - Greer, Joseph A.
AU - Vanderklish, Julie
AU - Rabideau, Dustin J.
AU - Cronin, Katherine
AU - Reynolds, Mathew
AU - Ufere, Nneka
AU - Rice, Julia
AU - Clay, Madison
AU - Newcomb, Richard
AU - DeFilipp, Zachariah
AU - Ho, Vincent
AU - Soiffer, Robert J.
AU - Pensak, Nicole
AU - Yi-Bin, Chen
AU - Temel, Jennifer S.
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2025/2
Y1 - 2025/2
N2 - BACKGROUND: Interventions to address sexual health in hematopoietic stem cell transplant (HSCT) survivors are limited.METHODS: We conducted a pilot randomized trial of a digital app, SHIFT (Sexual Health and Intimacy Following Transplant), to address sexual dysfunction in HSCT survivors who were ≥3 months post autologous or allogeneic HSCT. Patients were randomly assigned to SHIFT or enhanced usual care. All participants first underwent a brief physical examination by a trained HSCT clinician. Participants assigned to the intervention received access to SHIFT for 8 weeks. SHIFT consists of 5 modules addressing the biological, interpersonal, social, and psychological causes of sexual dysfunction. The primary endpoint was feasibility, defined a priori as ≥60% enrollment of eligible patients, and 60% of those assigned to SHIFT completing ≥70% of the modules. We assessed patient satisfaction with sex, interest in sex, orgasm pleasure (using the Patient-Reported Outcomes Measurement Information System [PROMIS]), quality of life (QoL; using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant [FACT-BMT]), and anxiety and depression symptoms (using the Hospital Anxiety and Depression Scale [HADS]) at baseline, 8 weeks, and 12 weeks. The preliminary effects of SHIFT on study outcomes were explored using analysis of covariance (ANCOVA) and estimates of effect size at 8 weeks (Cohen's d).RESULTS: We enrolled 64.2% (61/95) of eligible patients. Of those assigned to the intervention, 70.0% completed 4 of the 5 SHIFT modules and 66.7% completed all SHIFT modules. At 8 weeks, SHIFT participants reported improved satisfaction with sex (14.6 vs 12.3; d=0.46), interest in sex (6.7 vs 5.7; d=0.59), orgasm pleasure (9.7 vs 8.3; d=0.37), QoL (115.6 vs 108.3; d=0.45), and symptoms of anxiety (4.5 vs 6.4; d=0.47) and depression (3.6 vs 5.4; d=0.62) compared with the control group.CONCLUSIONS: The SHIFT digital app to address sexual dysfunction demonstrated feasibility and promising preliminary efficacy in improving sexual health outcomes, QoL, and psychological distress for HSCT survivors.
AB - BACKGROUND: Interventions to address sexual health in hematopoietic stem cell transplant (HSCT) survivors are limited.METHODS: We conducted a pilot randomized trial of a digital app, SHIFT (Sexual Health and Intimacy Following Transplant), to address sexual dysfunction in HSCT survivors who were ≥3 months post autologous or allogeneic HSCT. Patients were randomly assigned to SHIFT or enhanced usual care. All participants first underwent a brief physical examination by a trained HSCT clinician. Participants assigned to the intervention received access to SHIFT for 8 weeks. SHIFT consists of 5 modules addressing the biological, interpersonal, social, and psychological causes of sexual dysfunction. The primary endpoint was feasibility, defined a priori as ≥60% enrollment of eligible patients, and 60% of those assigned to SHIFT completing ≥70% of the modules. We assessed patient satisfaction with sex, interest in sex, orgasm pleasure (using the Patient-Reported Outcomes Measurement Information System [PROMIS]), quality of life (QoL; using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant [FACT-BMT]), and anxiety and depression symptoms (using the Hospital Anxiety and Depression Scale [HADS]) at baseline, 8 weeks, and 12 weeks. The preliminary effects of SHIFT on study outcomes were explored using analysis of covariance (ANCOVA) and estimates of effect size at 8 weeks (Cohen's d).RESULTS: We enrolled 64.2% (61/95) of eligible patients. Of those assigned to the intervention, 70.0% completed 4 of the 5 SHIFT modules and 66.7% completed all SHIFT modules. At 8 weeks, SHIFT participants reported improved satisfaction with sex (14.6 vs 12.3; d=0.46), interest in sex (6.7 vs 5.7; d=0.59), orgasm pleasure (9.7 vs 8.3; d=0.37), QoL (115.6 vs 108.3; d=0.45), and symptoms of anxiety (4.5 vs 6.4; d=0.47) and depression (3.6 vs 5.4; d=0.62) compared with the control group.CONCLUSIONS: The SHIFT digital app to address sexual dysfunction demonstrated feasibility and promising preliminary efficacy in improving sexual health outcomes, QoL, and psychological distress for HSCT survivors.
KW - Adult
KW - Cancer Survivors/psychology
KW - Female
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Humans
KW - Male
KW - Middle Aged
KW - Mobile Applications
KW - Pilot Projects
KW - Quality of Life
KW - Sexual Dysfunction, Physiological/etiology
KW - Sexual Dysfunctions, Psychological/etiology
KW - Sexual Health
KW - Survivors/psychology
UR - http://www.scopus.com/inward/record.url?scp=85217909945&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2024.7076
DO - 10.6004/jnccn.2024.7076
M3 - Article
C2 - 39938468
AN - SCOPUS:85217909945
SN - 1540-1405
VL - 23
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
M1 - e247076
ER -
